COVID-19 trials registries data warehouse

 Return to trial list

Trial - RBR-7f4mt9f


Column Value
Trial registration number RBR-7f4mt9f
Full text link
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

First author
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Gil De Santis

Contact
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

gil@hemocentro.fmrp.usp.br

Registration date
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

2021-03-18

Recruitment status
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Not recruiting

Study design
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

RCT

Allocation
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Randomized

Design
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Parallel

Masking
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Open label

Center
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

unclear

Study aim
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Treatment

Inclusion criteria
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Infection confirmed by SARS-CoV-2 (RT-PCR of oro / nasopharyngeal material, or by the detection of IgM-class anti-SARS-CoV-2 antibody, or IgA, associated with a clinical picture suggestive of the disease). respiratory failure: patient on mechanical ventilation or with satO2 ? 93% in room air. Maximum of 10 days from the onset of symptoms. Age between 18 and 80 years. Formal agreement (signing the free and informed consent form- FICF- by the participant or by a member of his family) to participate in the study (it is worth remembering that the majority, or the totality, of the patients will not be in clinical conditions to agree or not to the proposal to participate in the study, therefore, the possibility of acceptance by first-degree relative, or second-degree relative in the absence of the former).

Exclusion criteria
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Severe comorbidity (eg, heart failure, kidney failure, sickle cell disease, active cancer). Concomitant infection with another virus (eg HIV, hepatitis B and C virus, HTLV 1/2) or bacteria. History of severe blood transfusion allergy (including patients who have experienced this reaction during the first transfusion, or within six hours after completion, who will then not receive the second dose) will be excluded from the analysis. Participant who received the first dose of plasma within 72 hours of its allocation to the experimental group. Participant (or his relative) who has withdrawn his consent to participate at any stage of the study.

Number of arms
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

2

Funding
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Hemocentro de Ribeirão Preto

Inclusion age min
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

18

Inclusion age max
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

80

Countries
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Brazil

Type of patients
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Severe/critical disease at enrollment

Severity scale
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

7: Severe/critical disease at enrollment

Total sample size
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

0

primary outcome
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Survival rate in each group on day 30 of orotracheal intubation or diagnosis of respiratory failure.

Notes
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Phase
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Phase 2/Phase 3

Arms
Last imported at : Dec. 10, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

[{"arm_notes": "", "treatment_id": 322, "treatment_name": "Convalescent plasma", "treatment_type": "Convalescent plasma", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]